fingolimod hydrochloride has been researched along with Depression in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, T; Gan, X; Guo, Y; Long, X; Pu, S; Ren, C; Tang, H; Zhou, H | 1 |
| Englund, S; Fang, F; Frisell, T; Longinetti, E; Piehl, F; Reutfors, J | 1 |
| Amodio, N; Citraro, R; Constanti, A; De Sarro, C; De Sarro, G; Gallo Cantafio, ME; Leo, A; Russo, E | 1 |
| Al-Hussain, F; Al-Salloum, N; Alazwary, N; Daif, A; Howaidi, S; Saeedi, J | 1 |
| Amato, MP; Bartezaghi, M; Bergh, FT; Centonze, D; Comi, G; Filippi, M; Gallo, P; Mattioli, FC; Patti, F; Pozzilli, C; Rocca, MA; Saccà, F; Turrini, R | 1 |
| Cao, K; Li, L; Shi, D; Shi, M; Tian, T; Wen, S; Yao, S; Zhang, M; Zhou, H; Zhu, X | 1 |
| Cuda, CM; Der, E; Gadhvi, GT; Gulinello, M; Makinde, HM; Mike, EV; Putterman, C; Stock, A; Winter, DR | 1 |
| Comi, G; de Vera, A; Eckert, B; Gold, S; Kappos, L; Montalban, X; O'Connor, P | 1 |
2 trial(s) available for fingolimod hydrochloride and Depression
| Article | Year |
|---|---|
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing-remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study).
Topics: Adolescent; Adult; Cognition Disorders; Depression; Disability Evaluation; Electrocardiography; Executive Function; Female; Fingolimod Hydrochloride; Humans; Immunologic Factors; Interferon beta-1b; Longitudinal Studies; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Sclerosis, Relapsing-Remitting; Neuropsychological Tests; Pilot Projects; Statistics, Nonparametric; Treatment Outcome; Young Adult | 2017 |
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study.
Topics: Administration, Oral; Adult; Canada; Chi-Square Distribution; Depression; Double-Blind Method; Europe; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Placebos; Propylene Glycols; Psychiatric Status Rating Scales; Quality of Life; Sphingosine; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2011 |
6 other study(ies) available for fingolimod hydrochloride and Depression
| Article | Year |
|---|---|
Fingolimod suppressed the chronic unpredictable mild stress-induced depressive-like behaviors via affecting microglial and NLRP3 inflammasome activation.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Models, Animal; Fingolimod Hydrochloride; Hippocampus; Inflammasomes; Male; Maze Learning; Microglia; NLR Family, Pyrin Domain-Containing 3 Protein; Oxidative Stress; Rats; Rats, Sprague-Dawley; Sphingosine 1 Phosphate Receptor Modulators; Stress, Psychological | 2020 |
Risk of depression in multiple sclerosis across disease-modifying therapies.
Topics: Depression; Fingolimod Hydrochloride; Humans; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Prospective Studies; Recurrence | 2022 |
Fingolimod Exerts only Temporary Antiepileptogenic Effects but Longer-Lasting Positive Effects on Behavior in the WAG/Rij Rat Absence Epilepsy Model.
Topics: Animals; Anticonvulsants; Antidepressive Agents; Anxiety; Behavior, Animal; Brain; Depression; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Fingolimod Hydrochloride; Immunosuppressive Agents; Learning; Male; Memory; Rats, Transgenic; Rats, Wistar; Rotarod Performance Test; TOR Serine-Threonine Kinases | 2017 |
Depression, anxiety and stress severities in multiple sclerosis patients using injectable versus oral treatments.
Topics: Administration, Oral; Adult; Anxiety; Cross-Sectional Studies; Depression; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Injections; Interferon beta-1a; Interferon beta-1b; Male; Multiple Sclerosis, Relapsing-Remitting; Natalizumab | 2017 |
FTY720 attenuates behavioral deficits in a murine model of systemic lupus erythematosus.
Topics: Animals; Brain; Cytokines; Depression; Disease Models, Animal; Female; Fingolimod Hydrochloride; Immunologic Factors; Lupus Erythematosus, Systemic; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Inbred MRL lpr; Quality of Life; Signal Transduction; T-Lymphocytes | 2018 |
Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Sphingosine-1-Phosphate Signaling.
Topics: Animals; Astrocytes; Autoantibodies; Behavior Observation Techniques; Behavior, Animal; Brain; Cognition; Cytokines; Depression; Disease Models, Animal; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Lupus Vasculitis, Central Nervous System; Lysophospholipids; Mice; Mice, Inbred MRL lpr; Microglia; Receptors, Lysosphingolipid; Signal Transduction; Sphingosine; Treatment Outcome | 2018 |